Abbott Laboratories
ABT
#53
Rank
$228.78 B
Marketcap
$131.50
Share price
-1.16%
Change (1 day)
25.45%
Change (1 year)
Categories

Abbott Laboratories (ABT), (founding name: Abbott Alkaloid Company) is a global pharmaceutical company with around 73,000 employees in 150 countries. Abbott was founded in 1888 by Wallace C. Abbott (1857-1921) and is headquartered in Abbott Park, a northern suburb of Chicago, Illinois.

P/E ratio for Abbott Laboratories (ABT)

P/E ratio as of May 2025 (TTM): 16.9

According to Abbott Laboratories's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 16.8876. At the end of 2024 the company had a P/E ratio of 14.6.

P/E ratio history for Abbott Laboratories from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202414.6-56.18%
202333.430.59%
202225.6-27.43%
202135.2-18.34%
202043.13.71%
201941.6-22.4%
201853.6-74.09%
2017207412.58%
201640.4167.34%
201515.1-49.14%
201429.728.56%
201323.1

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
16.8-0.34%๐Ÿ‡บ๐Ÿ‡ธ USA
16.6-1.85%๐Ÿ‡บ๐Ÿ‡ธ USA
23.4 38.76%๐Ÿ‡บ๐Ÿ‡ธ USA
22.9 35.55%๐Ÿ‡บ๐Ÿ‡ธ USA
24.5 45.18%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
17.5 3.91%๐Ÿ‡บ๐Ÿ‡ธ USA
75.7 348.40%๐Ÿ‡บ๐Ÿ‡ธ USA
27.9 65.35%๐Ÿ‡ฌ๐Ÿ‡ง UK
17.5 3.60%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
31.5 86.76%๐Ÿ‡ฌ๐Ÿ‡ง UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.